Stemcell United FCF per Share
Free Cash Flow per Share of Stemcell United (SCU.AX) as of Sep 8, 2026.
Get this data via API
Financial Data API
FCF per Share
-0.00AUD
YoY
108.70%
Last updated:
Free Cash Flow per Share of Stemcell United is 2026 -0.00 AUD. Free Cash Flow per Share of Stemcell United was 2025 -0.00 AUD. It decreases by 108.70% lower compared to the previous year.
The Stemcell United FCF per Share history
3 Years
10 Years
25 Years
Max
FCF per Share
Date
FCF per Share
Jan 1, 2015
-0.00 AUD
Jan 1, 2016
-0.00 AUD
Jan 1, 2017
-0.00 AUD
Jan 1, 2018
-0.00 AUD
Jan 1, 2019
-0.00 AUD
Jan 1, 2020
-0.00 AUD
Jan 1, 2021
-0.00 AUD
Jan 1, 2022
-0.00 AUD
| YEAR | FCF per Share | YoY |
|---|---|---|
| -0.00AUD | +108.70% | |
| -0.00AUD | +13.29% | |
| -0.00AUD | +20.29% | |
| -0.00AUD | -57.27% | |
| -0.00AUD | +332.29% | |
| -0.00AUD | -70.18% | |
| -0.00AUD | +28.94% | |
| -0.00AUD | — |
Access this data via the Eulerpool API
Stemcell United Stock analysis
What does Stemcell United do? Stemcell United Ltd is an internationally operating company that is active in the field of stem cell research and therapy. It was founded in 2005 by British entrepreneur and scientist Dr. Samantha Phillips, who previously worked for the renowned Roslin Institute for Animal Genetics.
The business model of Stemcell United is based on the development and distribution of innovative therapies that are based on the use of stem cells as a foundation. The company primarily relies on close collaboration with leading research institutions and clinics worldwide to stay up to date with the latest research and develop products and services that are based on current knowledge and meet the highest quality standards.
The various divisions of Stemcell United include the development and production of stem cell-based therapies for diseases such as cancer, heart attack, dementia, and stroke. Additionally, the company also offers support and consultation in the field of clinical trials as well as training for doctors and researchers to improve and optimize the use of stem cell therapies.
Another important area of Stemcell United's business activities is the production and marketing of stem cells for research purposes. Both embryonic and adult stem cells are produced and provided to advance research in this field and gain new insights.
The products offered by Stemcell United mainly include stem cell preparations for wound healing and tissue regeneration, as well as specialized cell cultures for research in the field of stem cell therapy. These products are sold to clinics, research institutions, and end consumers and are available in many countries worldwide.
In recent years, Stemcell United has become one of the leading companies in the field of stem cell research and therapy and enjoys a high reputation in the industry. The company primarily relies on close collaboration with other top companies in the industry and a strong connection to research and development in this field.
Overall, Stemcell United is an innovative and dynamic company that sets standards in the field of stem cell research and therapy worldwide and constantly seeks new ways to utilize the possibilities of stem cell therapy for the health and well-being of humans and animals. Stemcell United is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Stemcell United stock
On Eulerpool you can find the complete historical development of Free Cash Flow per Share Stemcell United since 2006 – with annual values, charts, and detailed analysis.
FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.
Access this data via the Eulerpool API
Cash Flow — Stemcell United
Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A
All Key Metrics — Stemcell United
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth